Skip to main
  1. Stocks
  2. Danaher
  3. Forecast
DHR

Danaher (DHR) Stock Forecast & Price Target

Danaher (DHR) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Danaher is attractive because its 1984 transformation and later portfolio reshaping have left it concentrated in higher-quality life sciences and diagnostics, where recurring consumables, instruments, and bioprocessing demand support durable growth. Its 3Q26 results reinforced that thesis, with $6.55B in revenue, 3.0% core growth, 29.0% adjusted operating margin, $2.11 adjusted EPS, and $1.6B of free cash flow, while bioprocessing orders grew mid-teens and diagnostics improved ex respiratory. The combination of a more conservative 4% to 5% 2027 core growth starting point, improving end markets, easing headwinds, and continued capital deployment through tuck-in acquisitions supports a positive long-term outlook.

Bears say

Danaher is facing a fundamentally weaker growth profile because 4Q26 core growth is expected to slow to about +3.0%, below the Street’s +5.2% estimate, while respiratory alone creates roughly a 150 bp drag and revenue is forecast near $400M versus about $500M in 4Q25. Its Life Sciences business has lagged, instrument demand continues to decline, bioprocess equipment recovery has not materialized, and Diagnostics still faces China headwinds even as the company’s ability to offset these issues through M&A has come into question after several recent acquisitions failed to meet expectations. Although adjusted operating margin is still expected to be about 29.5% in 4Q26 and YTD adjusted EPS stands at $6.11 with margin at 28.7%, the lack of a full-year margin outlook and risks from weaker biopharma spending, lower research funding, and hospital lab softness support a negative outlook.

Danaher (DHR) has been analyzed by 16 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.

Danaher (DHR) Analyst Forecast & Price Prediction

Get the latest Danaher (DHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Danaher (DHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Danaher (DHR) Forecast

Analysts have given Danaher (DHR) a Buy based on their latest research and market trends.

According to 16 analysts, Danaher (DHR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $245.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $245.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Danaher (DHR)


Danaher (DHR) Analyst Forecast & Price Prediction

Get the latest Danaher (DHR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Danaher (DHR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DHR stock data and trends